Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE CHILDREN S ALLERGY versus EFIDAC 24 CHLORPHENIRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE CHILDREN S ALLERGY versus EFIDAC 24 CHLORPHENIRAMINE MALEATE.
AZELASTINE HYDROCHLORIDE CHILDREN'S ALLERGY vs EFIDAC 24 CHLORPHENIRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine hydrochloride is a phthalazinone derivative that acts as a selective histamine H1-receptor antagonist. It inhibits the release of histamine and other mediators from mast cells, reduces chemotaxis, and decreases eosinophil activation. It also suppresses leukotriene and cytokine production.
Chlorpheniramine maleate is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, preventing histamine-mediated allergic reactions. It also has anticholinergic and sedative properties due to central H1 receptor blockade.
Azelastine hydrochloride nasal spray: 1 spray (137 mcg) per nostril twice daily; maximum 2 sprays per nostril twice daily.
4 mg orally every 4-6 hours; maximum 24 mg/day.
None Documented
None Documented
Terminal elimination half-life is 22–25 hours in adults; steady state achieved in 3–5 days. In children (6–11 years), half-life is similar (mean 22 hours).
Terminal elimination half-life ranges from 14 to 25 hours (mean 20 hours) in adults; prolonged in hepatic or renal impairment (up to 50-60 hours in cirrhosis).
Primarily renal (approximately 75%), with about 50% as unchanged drug and 25% as metabolites via CYP3A4 and CYP2D6. Fecal excretion accounts for ~20%.
Renal excretion of unchanged drug and metabolites accounts for approximately 70-80% of elimination, with about 20-30% excreted via feces (biliary).
Category C
Category C
Antihistamine
Antihistamine